Possible risk for cardiac arrhythmia related to intravenous erythromycin.
OBJECTIVE
To evaluate the incidence of prolongation of the rate-corrected electrocardiographic QT interval (QTc) and of ventricular arrhythmia associated with intravenous administration of erythromycin lactobionate.


METHODS
A consecutive series of 7 critically ill patients treated with intravenous erythromycin for severe pneumonia.


METHODS
A medical intensive care unit of a university hospital.


RESULTS
Registration of QTc duration before and after intravenous administration of erythromycin as a short infusion. Blood chemistry, hemodynamic variables, arrhythmias, and co-medications were recorded. Evaluation of at least 10 ECG intervals by 2 experienced investigators who were blinded as to the time of drug administration. If several measurements were performed in the same patient, only the mean value was used for further analysis. During 12 of 13 drug administrations studied in 7 patients QTc prolongation was observed. The extent of QTc prolongation was significantly correlated with the infusion rate (mg/min, r = 0.765, p = 0.05). In 3 patients ventricular arrhythmia occurred in close temporal relation to the erythromycin infusion; two of them developed ventricular fibrillation shortly after the first and second dose of erythromycin, respectively, and died within 3 h.


CONCLUSIONS
In critically ill patients erythromycin-induced QTc prolongation is a frequent pharmacologic effect correlated with erythromycin infusion rate. To avoid changes in electrocardiographic intervals and thereby possibly potentially life-threatening ventricular arrhythmia administration with the lowest possible infusion rate and close cardiac rhythm monitoring are advisable in these patients.
Haefeli
W E
WE
Department of Internal Medicine, University Hospital (Kantonsspital), Basel, Switzerland.
Schoenenberger
R A
RA
Weiss
P
P
Ritz
R
R
D000368:Aged; D001145:Arrhythmias, Cardiac / Q000139:chemically induced / Q000175:diagnosis / Q000453:epidemiology*; D004562:Electrocardiography / Q000592:standards*; D004917:Erythromycin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D005260:Female; D006785:Hospitals, University; D006801:Humans; D007262:Infusions, Intravenous; D007362:Intensive Care Units; D016014:Linear Models; D008297:Male; D008875:Middle Aged; D008991:Monitoring, Physiologic; D011014:Pneumonia / Q000150:complications / Q000188:drug therapy*; D011446:Prospective Studies; D012307:Risk Factors; D013557:Switzerland / Q000453:epidemiology; D013997:Time Factors
C010948:erythromycin lactobionate; D004917:Erythromycin